The prevalence of heart failure (HF) with preserved ejection fraction (HFpEF) continues its yearly increase in the USA and now surpasses that of HF with reduced ejection fraction (HFrEF) [
9]. HFpEF is associated with high morbidity, mortality, and economic cost. Medications established as part of guideline-directed medical therapy have reduced hospitalization rates and cardiovascular morbidity and mortality for patients with HFrEF [
9]. However, most current drug therapies remain unsuccessful in improving clinical outcomes in patients with HFpEF. Therefore, other pharmacotherapies are urgently needed to effectively treat HFpEF. …